SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

UroGen Pharma Q1 EPS $(1.790) Misses $(1.620) Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.790) per share which missed the analyst consensus estimate of $(1.620) by 10.49 percent. This is a 61.26 percent decrease over losses of $(1.110) per share

Benzinga · 05/07/2020 12:38

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.790) per share which missed the analyst consensus estimate of $(1.620) by 10.49 percent. This is a 61.26 percent decrease over losses of $(1.110) per share from the same period last year.